Abstract: The invention relates to highly stable alcohol-free, water-glycerol solutions of T4 thyroid hormone, with a reduced amount of T3 impurity, packaged via specific container arrangements. The containers are multi-barrier ones, in which a number of layers of specific materials separate the solution from contact with the external environment.

Abstract: The invention relates to highly stable alcohol-free, water-glycerol solutions of T4 thyroid hormone, with a reduced amount of T3 impurity, packaged via specific container arrangements. The containers are multi-barrier ones, in which a number of layers of specific materials separate the solution from contact with the external environment.

Abstract: The invention relates to highly stable alcohol-free, water-glycerol solutions of T4 thyroid hormone, with a reduced amount of T3 impurity, packaged via specific container arrangements. The containers are multi-barrier ones, in which a number of layers of specific materials separate the solution from contact with the external environment.

Abstract: The invention relates to highly stable alcohol-free, water-glycerol solutions of T4 thyroid hormone, with a reduced amount of T3 impurity, packaged via specific container arrangements. The containers are multi-barrier ones, in which a number of layers of specific materials separate the solution from contact with the external environment.

Abstract: The invention relates to highly stable alcohol-free, water-glycerol solutions of T4 thyroid hormone, with a reduced amount of T3 impurity, packaged via specific container arrangements. The containers are multi-barrier ones, in which a number of layers of specific materials separate the solution from contact with the external environment.

Abstract: The invention relates to a new composite based on hydroxypropyl-?-cyclodextrin, sucralose, a pharmaceutically active ingredient (API) complexed in said hydroxypropyl-?-cyclodextrin, and optionally an aqueous vehicle. The composite is obtainable by a complexation process of the API in hydroxypropyl-?-cyclodextrin, carried out in the presence of sucralose. The composite ensures a surprisingly high API bioavailability through buccal route of absorption, due to a high absorption rate through the oral membrane. The composite is therefore suitable for the preparation of oromucosal pharmaceutical compositions, e.g. buccal or sublingual tablets, orodispersible film, etc., having high bioavailability.

Abstract: The invention relates to highly stable alcohol-free, water-glycerol solutions of T4 thyroid hormone, with a reduced amount of T3 impurity, packaged via specific container arrangements. The containers are multi-barrier ones, in which a number of layers of specific materials separate the solution from contact with the external environment.

Abstract: The present invention relates to new synergistic associations of hyaluronic acid sodium salt (HANa), verbascoside (VB) and glycero-phospho-inositol (GPI), and the use of said associations in therapy, in particular in the topical treatment of inflammatory and painful conditions of the mucosa and/or skin, such as dermatitis, acne, psoriasis, ulcers, decubitus ulcers, phlebitis, hemorrhoids, and in particular vulvodynia and urethritis.

Abstract: A pharmaceutical composition is described for the sublingual administration of progesterone in the form of a rapidly-disintegrating tablet, which is capable of promoting a greater bioavailability of the progesterone; a method for preparing said pharmaceutical composition is also described.

Abstract: A pharmaceutical composition is described for the sublingual administration of progesterone in the form of a rapidly-disintegrating tablet, which is capable of promoting a greater bioavailability of the progesterone; a method for preparing said pharmaceutical composition is also described.

Abstract: The present invention relates to a single-dose formulation for oral use of the thyroid hormones triiodothyronine or liothyronine (T3) and tetraiodothyronine or thyroxine (T4) in water-alcohol solution, which is physically and chemically stable, protected against accidental or microbiological contamination, in a container for pharmaceutical use which is squeezable and impermeable to the evaporation of the volatile substances it contains, and the corresponding means for implementing it.

Abstract: A pharmaceutical composition is described for the sublingual administration of progesterone in the form of a rapidly-disintegrating tablet, which is capable of promoting a greater bioavailability of the progesterone; a method for preparing said pharmaceutical composition is also described.

Abstract: A packaging includes a tray and a sheet. The tray has a series of spaced apart sections. Each spaced apart section is generally rectangular in shape and has a recessed compartment and an upper surface. The sheet is fixed in part to the upper surface of the tray and has a plurality of tab portions that are not fixed to the tray thereby creating a tab. Each tab portion corresponds to one of the spaced apart sections and has first and second ends. Each tab portion can be graduated in width from the first end to the second end. The first end can be positioned in a corner of the corresponding spaced apart section. The tab portion has a length measured parallel to the length of the corresponding spaced apart section and the second end is adjacent to the sealed portion of the sheet.

Abstract: A packaging having a tray (12) having at least one recess to receive contents therein and an upper layer. The packaging also has a manually removable sheet (16) that is fixed in part to the upper layer of the tray and unfixed in part to the tray, the unfixed part of the sheet being in the form of a tab (20). The tab is located adjacent to one corner of the upper portion of the tray that forms the recess, whereby when the sheet is fixed to the tray it is an effective seal against moisture and light. The packaging may have a peel off layer that may be manually removed for those with limited dexterity. The tab has a graduated width for easy grasping by the patient The tray does not need to be separated into subsections prior to removal of the contents therein.

Abstract: The present invention is a method for forming a composition in solid particulate form from a mixture of constituents, at least one of which is a liquid, the method comprising forming said composition from a mixture of constituents comprising a lipophilic liquid, a hydrophilic solid dispersant, and a solid particulating agent.

Abstract: The present invention relates to a pharmaceutical composition comprising an unpleasant-tasting therapeutic agent and skim milk powder. The composition of the present invention may further comprise a conventional pharmaceutical excipient. A further aspect of the present invention is a method of making a pharmaceutical composition comprising the step of dry blending a therapeutic agent having a substantially stable unpleasant taste and skim milk powder in an amount sufficient to mask the unpleasant taste of the therapeutic agent. The therapeutic agent and the skim milk powder are combined in a ratio sufficient to provide effective taste-masking of the therapeutic agent.

Abstract: The application discloses oral pharmaceutical compositions which are tasted in the mouth during administration. Fast-dissolving tablets, chewable tablets and effervescent dispersions are exemplified. To mask the taste of unpleasant-tasting active ingredients, it has been found that blending with cyclodextrin without the conventional complex formation is effective. Consequently more economical modes of manufacture such as simple granulation and dry blending can be used.